Chloe Burlot

Ms. Chloe Burlot

Student
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PCPowel Crosley
Powel Crosley
AFAnniina Farkkila
Anniina Farkkila
AJAdrianne Jenner
Adrianne Jenner
CBChloe Burlot
Chloe Burlot
OCOlivia Cardinal
Olivia Cardinal
MHMary M. Hitt
Mary M. Hitt
Granulosa cell tumors (GCT) constitute only ~5% of ovarian neoplasms yet have significant consequences, as up to 80% of women with recurrent GCT will die of the disease. This study investigated the effectiveness of procaspase-activating compound 1 (PAC-1), an activator of procaspase-3, in treating adult GCT (AGCT) in combination with selected apoptosis-inducing agents. Sensitivity of the AGCT cell line KGN to these drugs, alone or in combination with PAC-1, was tested using a viability assay. Our results show a wide range in cytotoxic activity among the agents tested. Synergy with PAC-1 was most pronounced, both empirically and by mathematical modelling, when combined with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). This combination showed rapid kinetics of apoptosis induction as determined by caspase-3 activity, and strongly synergistic killing of both KGN as well as patient samples of primary and recurrent AGCT. We have demonstrated that the novel combination of two pro-apoptotic agents, TRAIL and PAC-1, significantly amplified the induction of apoptosis in AGCT cells, warranting further investigation of this combination as a potential therapy for AGCT.

1 January 2024 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
MSMarylise Sterlé
Marylise Sterlé
APAlicja Puszkiel
Alicja Puszkiel
CBChloe Burlot
Chloe Burlot
EPEva Pereira
Eva Pereira
ABAudrey Bellesoeur
Audrey Bellesoeur
ASAntonin Schmitt
Antonin Schmitt
Background: Olaparib is an inhibitor of the human poly-(ADP-ribose)-polymerase enzymes (PARP1/2) needed to repair single-strand DNA breaks. It is used in breast, ovarian, prostate and pancreatic cancer. Objectives: This work aimed to describe the pharmacokinetics/pharmacodynamics (PK/PD) relationship between olaparib plasma concentrations and common adverse effects (i.e. anaemia and hypercreatininaemia), in a real-life setting, to propose a target concentration for therapeutic drug monitoring. Methods: Two PK/PD models describing the evolution of haemoglobinaemia and creatininaemia as a function of time were developed, based on data from, respectively, 38 and 37 patients receiving olaparib. The final model estimates were used to calculate the incidence of anaemia and creatinine increase according to plasma trough concentrations for 1000 virtual subjects to define target exposure. Results: The final models correctly described the temporal evolution of haemoglobinaemia and creatininaemia for all patients. The haemoglobinaemia PK/PD model is inspired by Friberg’s model, and the creatininaemia PK/PD model is an indirect response model. Model parameters were in agreement with physiological values and close to literature values for similar models. The mean (population) plasma haemoglobin concentration at treatment initiation, as estimated by the model, was 11.62 g/dL, while creatinine concentration was 71.91 µmol/L. Using simulations, we have identified a target trough concentration of 3500–4000 ng/mL, above which more than 20% of patients would report grade ≥3 anaemia. Conclusion: Based on real-world data, we were able to properly describe the time course of haemoglobinaemia and plasma creatininaemia during olaparib treatment.

17 June 2026 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
CBChloe Burlot
Chloe Burlot
FRFrançois Riglet
François Riglet
MRMathilde Romagnoli
Mathilde Romagnoli
ALAriane Leconte
Ariane Leconte
ADAudrey Delmas
Audrey Delmas
SFSylvain Fouliard
Sylvain Fouliard
This work aims to assess the S65487‐induced disruption of the B‐cell lymphoma‐2 (Bcl2)/Bcl2‐like protein 11 (Bim) complex at therapeutic doses via a pharmacokinetic/pharmacodynamic model and to reconcile pharmacokinetic data from microdoses and therapeutic doses in a single population pharmacokinetic model. The first model consists of a linear 3‐compartment pharmacokinetic model linked to an indirect response model with concentration‐dependent inhibition of Bcl2/Bim complex formation. Simulations predicted a 97.6% maximum reduction in complex formation with 1200 mg of S65487, following a sustained administration schedule and using characteristics from phase I/II patients. Before clinical trials were conducted in cancer patients, a microdose study was conducted in healthy volunteers. Although S65487 exhibited slightly nonlinear pharmacokinetics at therapeutic doses, pharmacokinetic parameters estimated after microdose administration differed substantially. Thus, several hypotheses were explored to reconcile the microdose and therapeutic data within a unified PK model. Nonlinearity in drug disposition emerged as the most biologically plausible explanation. A Michaelis–Menten approximation of the target‐mediated drug disposition model was applied to elimination and distribution processes to estimate parameters through saturable pathways. Performance of this second model, the microdose optimized pharmacokinetic model, was evaluated by comparing population predicted and observed area under the curve. This optimized model demonstrated significant improvement, reducing the difference in the description of exposure for the microdose study from 5‐ to 1‐fold, without compromising the description at therapeutic doses. This modified model has a wider range of applicability across doses and could support the extrapolation of microdose study results to therapeutic doses in future research.